US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment | Reuters

FDA approves GSK's hepatitis B drug Hibsago

The FDA approved GSK's hepatitis B drug Hibsago, allowing patients with the liver infection to maintain viral control after stopping long-term treatment. The approval offers a new treatment option for chronic hepatitis B patients.